Clinical Trial Update: Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase II trial evaluating combination immunotherapy with NeuVax and Trastuzumab in high-risk HER2-positive breast cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• NeuVax (nelipepimut-S)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Cancer Insight, LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-12-12